Advice

following a full submission assessed under the ultra-orphan medicine process:

conestat alfa (RuconestĀ®) is accepted for use within NHSScotland.

Indication under review: For treatment of acute angioedema attacks in adults and adolescents with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency.

Conestat alfa was associated with a significantly shorter time to relief from symptoms of HAE attack compared with placebo during controlled phase III studies.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of conestat alfa. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.

Download detailed advice154KB (PDF)

Download

Medicine details

Medicine name:
conestat alfa (Ruconest)
SMC ID:
745/11
Indication:
Treatment of acute angioedema attacks in adults and adolescents with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency
Pharmaceutical company
Pharming Group NV
BNF chapter
Respiratory system
Submission type
Full
Status
Accepted
Date advice published:
13 August 2018